Passive immunotherapy of viral infections: 'super-antibodies' enter the fray

Key Points

  • Antibodies have been used for over a century prophylactically and, less often, therapeutically against viruses.

  • 'Super-antibodies' — a new generation of highly potent and/or broadly cross-reactive human monoclonal antibodies — offer new opportunities for prophylaxis and therapy of viral infections.

  • Super-antibodies are typically generated infrequently and/or in a limited number of individuals during natural infections.

  • Isolation of these antibodies has primarily been achieved by large-scale screening for suitable donors and new single B cell approaches to human monoclonal antibody generation.

  • Super-antibodies may offer the possibility of treating multiple viruses of a given family with a single reagent. They are also valuable templates for rational vaccine design.

  • The great potency of super-antibodies has many advantages for practical development as therapeutic reagents. These advantages can be enhanced by a variety of antibody engineering technologies.


Antibodies have been used for more than 100 years in the therapy of infectious diseases, but a new generation of highly potent and/or broadly cross-reactive human monoclonal antibodies (sometimes referred to as 'super-antibodies') offers new opportunities for intervention. The isolation of these antibodies, most of which are rarely induced in human infections, has primarily been achieved by large-scale screening for suitable donors and new single B cell approaches to human monoclonal antibody generation. Engineering the antibodies to improve half-life and effector functions has further augmented their in vivo activity in some cases. Super-antibodies offer promise for the prophylaxis and therapy of infections with a range of viruses, including those that are highly antigenically variable and those that are newly emerging or that have pandemic potential. The next few years will be decisive in the realization of the promise of super-antibodies.


The use of antibodies to ameliorate the adverse clinical effects of microbial infection can be traced back to the late 19th century and the work of von Behring and Kitasato on the serum therapy of diphtheria and tetanus (reviewed in Refs 1,2). In these settings, the antibodies act to neutralize bacterial toxins. Therapies followed in which serum antibodies were targeted directly against bacterial and then viral pathogens. For viral pathogens, enriched polyclonal IgG molecules from immunized animals were shown to be effective in prophylaxis, and even prophylaxis after exposure, for a number of viruses, including hepatitis A virus, hepatitis B virus, hepatitis C virus, herpes simplex virus, measles virus, rabies virus, respiratory syncytial virus (RSV), smallpox virus and varicella zoster virus. In general, the effectiveness of antibody preparations declined with the duration of infection such that they were often regarded as poor therapeutic options. Of course, the major antiviral strategy of the 20th century was vaccination.

Over the latter part of the 20th and early part of the 21st century, there have been major developments in our understanding of antibodies and our ability to manipulate them. The advent of hybridoma technology in 1976 provided a reliable source of mouse monoclonal antibodies (mAbs), the first impact of which was not on antibody therapy but on the characterization of cells through the definition of cell surface markers. Broad implementation of mAbs in therapy had to wait until the development of humanized mouse antibodies and then the generation of fully human antibodies by various techniques described below. Such antibodies have been largely applied in the fields of oncology and autoimmunity. Only a single antiviral mAb, the RSV-specific antibody palivizumab, is in widespread clinical use. The reasons for this have been discussed elsewhere1,3,4,5,6, although perhaps the most important reasons are the fairly high cost of the production of mAbs, the difficulties of administration and a belief that antibodies are largely effective only in a prophylactic setting, which can be achieved for many viruses by vaccination.

However, as we discuss here, an increasing number of antiviral antibodies with quite remarkable properties in terms of potency and/or cross reactivity with other viruses or strains of the same virus are being isolated. These so-called super-antibodies are changing our understanding of what we can hope to achieve with antibodies against microbial infection in the clinic. Increased potency can greatly reduce the unit costs of treatment, make alternative routes of administration feasible and extend the effective half-life of the antibody. Increased cross reactivity can allow us to consider targeting multiple viruses with single antibodies. Antibody engineering can impact both potency and cross reactivity and can greatly extend the half-life of super-antibodies.

In this Review, we discuss how new approaches have fuelled the identification of super-antibodies, where and how such antibodies may be best applied and future directions for the field.

Super-antibody discovery

Many acute viral infections induce robust neutralizing antibody responses in the large majority of individuals. In general, these viruses show little evidence for evasion of antibody responses, and we have referred to them as 'evasion lite' viruses7. Typically, they either display limited antigenic variability in their surface protein (or proteins) or show considerable variability but nevertheless express immunodominant, conserved epitopes. Examples of viruses in this category include measles virus, poliovirus, chikungunya virus and RSV8,9,10,11. The life cycle of these viruses presumably does not dictate immune evasion. For these types of viruses, the isolation of super-antibodies from immune donors has been achieved in a fairly straightforward manner8,9,12,13,14. However, some viruses have evolved mechanisms to evade effective neutralizing antibody responses (termed 'evasion strong' viruses) and induce such responses at much lower levels. Effective responses in the context of infection with highly antigenically variable viruses refers not only to their neutralization potency but also to their effectiveness against diverse circulating global isolates, often referred to as breadth. For these viruses — including HIV, influenza virus, Ebola virus and Lassa virus — only a proportion of infected individuals, sometimes quite small, will generate broad and potent neutralizing antibody responses15,16,17,18,19,20,21. Furthermore, within these individuals, potent broadly neutralizing antibody (bnAb) specificities generally constitute only a small fraction of the antigen-specific memory B cell pool.

For example, only a small percentage of HIV-infected individuals develop broad and potent serum responses over time, and B cell cloning efforts have demonstrated that bnAbs generally comprise <1% of the HIV envelope (Env)-specific memory B cell repertoire22. Although there are probably multiple factors that contribute to the low abundance of bnAbs within these individuals, the intrinsic nature of the viral Env protein likely has a key role. The HIV Env protein has evolved a multitude of mechanisms to evade bnAb responses, including decoy forms of Env, enormous antigenic variability, an evolving glycan shield, immunodominant and variable epitopes and poorly accessible conserved epitopes23. Furthermore, most HIV-specific bnAbs incorporate unusual features for epitope recognition, such as uncommonly long (or short) complementarity determining region 3 (CDR3) loops, insertions and deletions, tyrosine sulfation and extensive somatic hypermutation, that likely also contribute to the rarity and delayed development of bnAbs during natural infection24,25,26.

In the case of influenza virus infection, the vast majority of neutralizing antibodies elicited by infection or vaccination bind to variable epitopes within the haemagglutinin (HA) globular head of the viral particles and display strain-specific neutralizing activity27. Influenza virus-specific bnAbs typically target the conserved HA stem, but this region has variable immunogenicity28,29,30,31. The relatively low frequency of bnAbs against the HA stem is perhaps due to the typically tight packing of HA trimers on the virus surface, which may limit antibody accessibility to this region. For Ebola and Lassa viruses, extensive glycosylation on the surface Env proteins results in masking of conserved neutralizing epitopes15,32. In cases where super-antibodies are present at low frequency within immune repertoires, large-scale donor screening and high-throughput B cell isolation platforms have proved to be critical for the discovery of super-antibodies. Over the past several years, technological advances in these two areas have led to the identification of large numbers of super-antibodies, mostly from infected individuals, against a plethora of viral pathogens.

Large-scale donor screening. In the case of HIV, which has served as a prototype virus for many studies in this field33, systematic selection of donors with broadly neutralizing serum responses has proved to be critical for the identification of super-antibodies. Before 2009, the HIV field had been operating with a handful of bnAbs, all of which were limited either in breadth or in potency34. A number of factors complicated the identification of bnAbs, including the inefficiency of traditional approaches to mAb discovery, the small fraction of B cells that secrete bnAbs and the limited availability of samples from donors who had developed broad and potent neutralizing serum responses. Beginning in 2005, the problem of limited samples was addressed by establishing donor screening programmes to identify HIV-infected individuals with broadly neutralizing serum responses to serve as source material for the generation of bnAbs18,19,35,36. In one of the largest studies, 1,800 HIV-infected individuals from Australia, Rwanda, Uganda, the United Kingdom and Zambia were screened for broadly neutralizing sera using a reduced pseudovirus panel representative of global circulating HIV isolates19. A subset of individuals, termed 'elite neutralizers', was identified that exhibited exceptionally broad and potent neutralizing serum responses and was therefore prioritized for bnAb isolation.

Over the past 8 years, mining of these and similar samples has led to the identification of dozens of remarkably broad and potent HIV super-antibodies37,38,39,40,41. Careful selection of donors with desirable serum profiles has also enabled the isolation of rare super-antibodies to influenza virus, RSV, human metapneumovirus (HMPV), rabies virus and Zika virus12,42,43,44. For example, the pan-influenza A virus-neutralizing mAb FI6 and the RSV and HMPV cross-neutralizing mAb MPE8 were isolated from donors who were selected on the basis of their strong heterotypic serum responses12,42. Similarly, two pan-lyssavirus-neutralizing mAbs, called RVC20 and RVC58, were isolated from the memory B cells of four donors who exhibited potent serum-neutralizing activity against multiple lyssavirus species43.

High-throughput human B cell isolation technologies. Human antiviral neutralizing mAbs have been isolated using various different technologies, including combinatorial display libraries, human immunoglobulin transgenic mice and single B cell isolation methods (Fig. 1). Although all of these technologies have proved valuable for mAb generation, the recent burst in super-antibody discovery has primarily been driven by advances in single B cell-based methods. There are several possible reasons for this, including inefficiencies in combinatorial library generation and interrogation (leading to the loss of rare clones), altered binding characteristics of antibody fragments produced in heterologous expression systems (for example, Escherichia coli or yeast), constraints on the generation of suitable recombinant antigens for immunization or library selections, the loss of native heavy-chain and light-chain pairing during immune library generation and inherent differences between the adaptive immune systems of humanized mice and humans45.

Figure 1: Technologies for monoclonal antibody generation.

a | Combinatorial display libraries. Human antibody heavy-chain and light-chain genes are amplified by reverse transcription (RT)-PCR, and antibody fragments are displayed on the surface of a particle or cell in which the antibody genes are found (such as phage, yeast or mammalian cells142,143,144,145). Successive rounds of enrichment are performed to select for clones that bind to the target antigen. Genes encoding antibodies of interest are cloned into human IgG expression vectors to produce monoclonal antibodies (mAbs). b | Human immunoglobulin transgenic mice are generated by introducing human immunoglobulin loci into the mouse genome146,147. Upon immunization, the transgenic mice produce fully human antigen-specific antibodies. The B cells harvested from the immunized mice are fused with myeloma cells to generate antibody-secreting hybridomas, which are then screened for binding or functional activity. c | Single B cell cloning. Antigen-specific memory B cells or plasmablasts are single-cell sorted by flow cytometry, and cognate heavy-chain (Vh) and light-chain (Vl) variable genes are amplified by single-cell PCR57,58,148. The antibody variable genes are cloned into human IgG expression vectors to produce mAbs. d | Memory B cell immortalization. Memory B cells are immortalized by Epstein–Barr virus (EBV), and B cell culture supernatants are screened for binding or functional activity149. Positive cultures are subcloned by limiting dilution. e | Memory B cell culture. Single B cells are activated and cultured, and B cell supernatants are screened for binding or functional activity37,150. Antibody variable genes are amplified from clones of interest by PCR and cloned into human IgG expression vectors to produce mAbs. FACS, fluorescence-activated cell sorting.

PowerPoint slide

Several technological breakthroughs in the B cell cloning arena have been most critical in fuelling super-antibody identification. One of these advances came in 2009, when direct functional screening of thousands of B cell clones from an HIV elite neutralizer led to the isolation of two super-antibodies, PG9 and PG16, that were approximately an order of magnitude more potent than first-generation bnAbs37. Notably, PG9 and PG16 bind poorly to recombinant Env proteins and thus would not have been identified without direct functional screening of B cell supernatants. To date, many dozens of HIV-specific bnAbs targeting a diverse range of epitopes have been identified using functional screening approaches39,46,47,48. Highly potent super-antibodies to RSV, HMPV, Lassa virus and human cytomegalovirus (HCMV) have also been discovered using high-throughput functional screening technologies12,13,49,50 (Table 1).

Table 1 Antiviral super-antibodies

Similar to PG9 and PG16, these super-antibodies were isolated by screening B cell supernatants on the basis of their capacity to neutralize infection in vitro and were subsequently found to react poorly with currently available recombinant Env proteins. In the case of RSV, this approach led to the isolation of the highly potent mAb D25, which binds to an epitope that is exclusively expressed on the prefusion conformation of RSV fusion glycoproteins (F proteins)49,51. An engineered variant of mAb D25 (MEDI8897), which exhibits 50–100 times greater neutralization potency than palivizumab, is now being tested in clinical trials for the prevention of RSV-associated disease in high-risk infants. A second RSV prefusion F protein-specific super-antibody, which cross-neutralizes several different paramyxoviruses, including HMPV, was also isolated by screening B cell supernatants for neutralizing activity12 (Table 1).

In the case of HCMV, direct functional screening enabled the isolation of highly potent super-antibodies specific for conformational epitopes within the gH–gL–UL128–UL130–UL131A pentamer complex, which was not previously known to be a target for neutralizing antibodies13. Direct functional screening approaches have also led to the discovery of potent super-antibodies to Middle East respiratory syndrome coronavirus (MERS-CoV), Ebola virus, influenza virus, chikungunya virus, rabies virus and the poxvirus family9,42,43,52,53,54,55,56. Notably, in the case of MERS-CoV, only 1 B cell culture out of 4,600 screened showed neutralizing activity53. Similarly, the pan-influenza A virus-neutralizing mAb FI6 was isolated by testing 104,000 plasma cells from eight immune donors42. Finally, only 2 of 500 mAbs that were selected on the basis of their ability to neutralize rabies virus showed cross-neutralizing activity against multiple lyssavirus species43. These examples clearly illustrate that exhaustive interrogation of immune repertoires is often required for the identification of rare cross-neutralizing super-antibodies.

A second breakthrough in the HIV antibody field followed the development of technology for antigen-specific single B cell sorting57,58,59. This approach, coupled with the use of rationally designed Env probes, allowed for the discovery of two new potent HIV-specific bnAbs that target the conserved CD4 binding site60,61 (Table 1). Following this discovery, several other potent bnAbs against the CD4 binding site were isolated through the use of similar approaches38,62,63. Recently, advances in the generation of recombinant native-like HIV Env trimers have enabled the identification of exceptionally potent 'PG9-class' bnAbs40.

Many HIV super-antibodies have now been generated with the use of single B cell sorting technology38,40,60,62,63. The use of fluorescently labelled probes to sort antigen-specific memory B cells has also enabled the discovery of highly potent super-antibodies to Ebola virus, RSV, human papilloma virus (HPV), Zika virus and influenza virus11,30,31,44,64,65. In the case of Ebola virus, a large-scale single B cell cloning effort led to the isolation of several hundred mAbs specific for Ebola virus envelope glycoprotein (GP), two of which showed potent pan-Ebola virus-neutralizing activity and protective efficacy64,66. A similar effort in the RSV field allowed for the isolation of several prefusion F-protein-specific mAbs that show over 100 times more potent neutralizing activity than palivizumab11. In addition, multiple groups have used clever dual-antigen labelling strategies to identify potent bnAbs to HIV, influenza virus, Ebola virus and HPV30,31,40,65,67,68. The structures of several super-antibodies bound to their viral targets are shown in Figure 2. Finally, a recent report showed that bnAbs to HIV can be readily elicited in cows through the use of a single Env trimer immunogen and that this induction depends on the long heavy-chain CDR3 loops of the bovine immunoglobulin repertoire67. It is possible that this repertoire may provide advantages in generating super-antibodies against other pathogens.

Figure 2: Structures of super-antibodies bound to their target antigens.

a | Cryoelectron microscopy structure of the broadly neutralizing anti-HIV-1 antibody PGT145 in complex with a recombinant HIV envelope (Env) trimer. PGT145 binds to a glycan-dependent quaternary epitope at the trimer apex152. b | Crystal structure of the influenza virus group 1 and group 2 neutralizing antibody CR9114 in complex with influenza virus haemagglutinin (HA). CR9114 recognizes a highly conserved epitope in the HA stem154,155. c | Crystal structure of the respiratory syncytial virus (RSV) and human metapneumovirus cross-neutralizing antibody MPE8 in complex with a stabilized RSV prefusion fusion glycoprotein trimer. d | Crystal structure of the Zika virus and dengue virus cross-neutralizing antibody C8 in complex with a soluble Zika virus Env ectodomain. C8 targets a quaternary epitope that bridges two Env protein subunits. Part a is adapted from Ref. 151, CC-BY-4.0. Part b is adapted with permission from Ref. 153, AAAS. Part c is adapted from Ref. 156, Macmillan Publishers Limited. Part d is adapted from Ref. 85, Macmillan Publishers Limited.

PowerPoint slide

Vaccination or infection-induced antibody-secreting cell (ASC) responses have also proved to be a rich source of antigen-specific antibodies. Following early studies that showed that a transient but large population of ASCs appears in peripheral blood 5–7 days after tetanus toxoid booster vaccination69, it was shown that influenza virus vaccination produced a similar ASC response and that the large majority of mAbs cloned from these cells bound with high affinity to influenza virus, providing a proof of concept that the ASC response could be exploited to rapidly generate antigen-specific antibodies against any immunizing antigen70. To date, plasmablast cloning has led to the isolation of mAbs against many different viruses, including dengue virus, Zika virus, HIV, influenza virus, vaccinia virus and rotavirus29,71,72,73,74,75,76.

One of the advantages of the plasmablast approach is that antigen baiting is not required for B cell sorting, thereby allowing for the isolation of antibodies that target epitopes that are poorly presented on recombinant antigens. For example, in the case of dengue virus, potent bnAbs targeting E-dimer-dependent epitopes were isolated using this approach72. However, it is important to emphasize that the ability to isolate super-antibodies using this method will depend on several factors. First, during a primary infection, the ASC population will be mainly composed of activated, low-affinity naive B cells (rather than affinity-matured memory B cells), making the possibility of identifying super-antibodies extremely unlikely. Second, in the context of a booster vaccination or secondary infection with an antigenically similar virus, most of the plasmablast response will be directed against immunodominant epitopes, which in many cases are not targeted by effective neutralizing antibodies. In such cases, exhaustive cloning, production and characterization of the plasmablast-derived mAbs would likely be required to identify rare super-antibodies. By contrast, secondary infection with an antigenically related but sufficiently divergent virus can drive the preferential expansion of B cells that target highly conserved epitopes, as exemplified by the unusually high frequency of bnAbs induced in donors who were infected with the novel H1N1 influenza virus in 2009 (Refs 29,75). In principle, one could use this type of approach for the generation of super-antibodies in humanized mice or other animal models by using suitably designed immunogens and immunization regimens.

Rapid response platforms for emerging viruses

Over the past two decades, humanity has faced a newly emerging, or re-emerging, viral threat almost every year, including severe acute respiratory syndrome coronavirus (SARS), West Nile virus, pandemic influenza virus, Ebola virus, MERS-CoV and Zika virus. Because of their comparatively fast path to approval and generally favourable safety profiles, mAb therapies represent a promising alternative to vaccines and small-molecule drugs for the treatment and prevention of emerging viral threats. Recently, several laboratories have demonstrated the feasibility of identifying, characterizing and scaling-up production of highly potent mAbs in remarkably short time frames.

In response to the 2014–2015 MERS-CoV outbreak, two different groups illustrated the power of their mAb discovery platforms by isolating highly potent MERS-specific mAbs, producing the mAbs in gram quantities and testing the lead mAbs in animal models at an unprecedented speed53,77. In one of these studies, a single highly potent MERS-CoV-neutralizing mAb was identified from the memory B cells of a convalescent donor through the use of a high-throughput functional screening approach53. This mAb, called LCA60, showed protection both before and after exposure in a mouse model of MERS-CoV infection. Importantly, this process took the authors only 4 months from the initial B cell screening to the development of a stable cell line that produces the neutralizing mAb at 5 g l−1. In the second study, human immunoglobulin transgenic mice were immunized with the MERS-CoV spike protein and then used to generate a panel of potent MERS-CoV-specific neutralizing mAbs within several weeks77. The authors also quickly generated a humanized mouse model of MERS-CoV infection, which was used to demonstrate the therapeutic efficacy of their mAbs.

In a third study, vaccination of transchromosomal cows engineered to produce fully human IgG molecules with MERS-CoV was shown to yield high serum titres of MERS-CoV-specific neutralizing antibodies78. Importantly, administration of the purified polyclonal transchromosomal bovine human IgG to mice either 12 hours before or 24 and 48 hours after MERS-CoV infection resulted in a significant reduction in viral lung titres. Transchromosomal bovines have also been used to rapidly generate polyclonal neutralizing antibodies to Hanta virus, Venezuelan equine encephalitis virus and Ebola virus79,80,81, demonstrating the feasibility of using this platform to rapidly generate therapeutics to combat emerging viral threats. The antibodies arising from transchromosomal cows are polyclonal to date, but there is potential for mAb isolation.

Between 2015 and 2016, several groups responded to the 2014–2015 Ebola virus outbreak by swiftly generating highly potent Ebola virus GP-specific neutralizing mAbs from the memory B cells of convalescent donors54,55,56,64,66. Many of these mAbs showed potent therapeutic efficacy against either Ebola or Bundibugyo virus after exposure in animal models and a subset showed protective efficacy against multiple Ebola virus strains54,55,64,66. Similarly, several groups have recently reported on the isolation of potent Zika-virus-specific neutralizing mAbs from human donors14,44,82,83. Notably, one of these neutralizing mAbs, called ZIKV-117, showed protection against Zika virus after exposure in both pregnant and nonpregnant mice82.

In certain cases, the availability of super-antibodies that target highly conserved epitopes may shorten timelines further by bypassing the need for mAb discovery. For example, it was recently shown that a subset of dengue-virus-specific mAbs potently cross-neutralizes Zika virus84,85,86. These bnAbs — perhaps carrying Fc mutations that ablate Fc receptor binding to avoid the potential for antibody-dependent enhancement14 — could immediately be used for prophylaxis for pregnant women living in Zika-virus-endemic regions. Notably, cocktails of super-antibodies targeting different epitopes, or bispecific or trispecific super-antibody constructs, will likely be required to prevent neutralization escape87,88,89,90,91,92,93.

Antibodies in prophylaxis and therapy

Antibodies can function against viruses by several mechanisms, primarily divided into activities against free virus particles and activities against infected cells. Neutralization, measured in vitro as the ability of an antibody to prevent viral entry into target cells without a requirement for involvement of any other agents, is an activity against free virions that has been most correlated with protection in vivo. Activities against infected cells generally depend on Fc effector functions and involve host effector cells. They include antibody-dependent cellular cytotoxicity (ADCC), complement-dependent cytotoxicity and antibody-dependent cellular phagocytosis (ADCP). It is presumed that these activities are likely to be important in antibody-based therapy. Because neutralization frequently correlates with the ability to bind to native structures on the virion surface, it can give some indication of the ability of antibodies to mediate effector activities such as ADCC and ADCP. The potency of super-antibodies is then often estimated from neutralization measurements, although ultimately it is of course in vivo activity that is crucial.

Prophylaxis. Vaccination is the most effective and low-cost method of preventing viral disease. However, the development of effective vaccines against many important viral pathogens — including HIV, RSV, hepatitis C virus, dengue virus and HCMV — has been met with limited success. Furthermore, vaccine development is a long complex process, often lasting 10–15 years, making immunization an impractical means of protecting individuals from newly emerging viral threats unless pan-virus family vaccines can be developed. For example, if antibodies can be identified that potently neutralize existing strains of Ebola virus, or even Ebola and Marburg filoviruses, then one could anticipate that a vaccine templated from the antibodies would also be effective against emerging strains of Ebola virus. However, at the current time, passive antibody prophylaxis represents a promising alternative to vaccination for a number of viral infections.

Currently, three purified polyclonal hyperimmune globulins derived from human donors immune to hepatitis B virus, HCMV or varicella zoster virus are on the market for the prevention of serious diseases associated with these viruses. A rabies-virus-specific immune globulin, combined with vaccination, is also available for prophylaxis after exposure. In 1998, palivizumab — a humanized mAb that targets the RSV F protein — became the first antiviral mAb approved by the US Food and Drug Administration. Palivizumab soon replaced the RSV hyperimmune globulin (RespiGam) for the prevention of severe RSV-associated disease in high-risk infants. However, although palivizumab is more specific and 50–100 times more potent than RespiGam, the cost associated with the required dosing makes its use impractical for all infants94. A second-generation RSV-specific mAb, which shows up to 50 times greater neutralization potency than palivizumab and contains substitutions in the Fc domain that extend its serum half-life, is currently in phase II clinical trials for the prevention of severe RSV-associated disease in all infants95 (Table 2).

Table 2 Antiviral monoclonal antibodies in clinical development

Although palivizumab is the only commercially available mAb for the prevention of a viral disease, there are multiple antiviral mAbs in preclinical and clinical development that have shown efficacy prior to exposure in animal models. For example, the potent MERS-CoV-specific mAbs described above were shown to prophylactically protect humanized mice against MERS-associated disease. Similarly, mAbs to chikungunya virus, influenza virus, HIV and Ebola virus have shown potent prophylactic efficacy in animal models9,85,96,97,98,99,100,101,102. Recently, a broadly neutralizing anti-Zika virus mAb (ZIKV-117) was shown to protect against maternal–fetal transmission in a mouse model of Zika virus infection82. If this observation translates to humans, prophylaxis with ZIKV-117 or similar neutralizing mAbs may be a promising means of protecting at-risk pregnant women against Zika virus infection and fetal transmission.

In the case of HIV, multiple studies have shown that passively administered neutralizing mAbs provide protection against intravenous, vaginal, rectal and oral challenge in nonhuman primate and mouse models99,100,101,103,104,105,106. A large ongoing study (the Antibody-Mediated Prevention (AMP) study will assess the ability of the VRC01 mAb specific for the CD4 binding site to decrease the risk of HIV acquisition in humans. Although animal studies have provided proof of principle that a vaccine capable of inducing sufficient titres of bnAbs could prevent the establishment of HIV infection in humans, and the AMP study will investigate this directly, the design of immunogens that efficiently elicit these rare antibodies remains a formidable challenge.

To bypass the challenges associated with active vaccination against HIV, a number of groups have proposed alternative strategies on the basis of vector-mediated antibody gene transfer to express bnAbs in vivo107. Unlike traditional passive immunization, which would require long-term repeated treatment with bnAbs, vectored immunoprophylaxis involves only a single injection and enables continuous and sustained delivery of antibodies. In 2009, pioneering work demonstrated that vector-mediated delivery of antibody-like molecules can provide vaccine-like protection against simian immunodeficiency virus (SIV) challenge in nonhuman primate models108. Subsequent studies have shown that vectored immunoprophylaxis is also compatible with full-length IgG molecules and CD4-like molecules109,110,111. If the preclinical results in mice and macaques translate to humans, vectored antibody gene delivery strategies could provide an alternative form of prophylaxis against HIV and other challenging vaccine targets, such as hepatitis C virus, pandemic influenza virus and malaria. Recently, nonviral vector nucleic acid delivery technologies have also been developed to obviate the potential safety issues associated with viral vector-mediated delivery, such as long-term persistence and potential viral DNA integration into the host genome112,113,114,115,116,117. In a recent study, it was shown that the administration of lipid-encapsulated nucleoside-modified mRNAs encoding the heavy-chain and light-chain genes of the broadly neutralizing HIV-1-specific antibody VRC01 to humanized mice resulted in high serum antibody concentrations and protection against intravenous HIV-1 challenge114.

Similar proof-of-concept studies have also been performed using synthetic DNA plasmid-mediated antibody gene transfer112,113. In one such study, synthetic DNA plasmids encoding cross-neutralizing anti-dengue virus antibodies were delivered to mice by electroporation and resulted in biologically relevant levels of serum antibody112. Importantly, a single intramuscular injection of plasmid DNA conferred protection against severe dengue disease in a mouse model. Although several technical challenges remain to be addressed, such as enhancing in vivo antibody expression levels and reducing the potential for immunogenicity, these studies demonstrate the feasibility of utilizing plasmid DNA and modified mRNA-based antibody delivery technologies for passive immunotherapy.

Therapy. Conventional wisdom says that antibodies are effective if present before or shortly after viral exposure, but their effectiveness declines markedly once infection is established. For example, the anti-RSV antibody palivizumab is effective in the clinic prophylactically but not therapeutically118. However, there are indications that the dogma may be challenged by super-antibodies. An example is the ability of a new generation of bnAbs against HIV to strongly impact ongoing infection in animal models87,119,120 in which an earlier generation of less-potent mAbs had very limited effects121. This ability likely reflects the increased neutralization potency of the super-antibodies as well as the increased breadth of neutralization that may restrict virus escape pathways119. A number of super-antibodies are now being evaluated in humans for their activities against established HIV infection122–126 (Table 2). Initial results are interesting, providing for example an indication of enhanced immune responses following bnAb administration127. The emerging results will be followed closely, including in the context of combining bnAbs with drugs and other antiviral agents to attempt HIV cure.

For other viruses, clear evidence of a strong therapeutic effect for super-antibodies has not been gathered yet. Several cases such as antibody treatment of rabies virus and Junin virus infections43,128 are probably better interpreted as prophylaxis after exposure rather than therapy for an established infection. Two promising examples of possible therapy are the successful treatment of Ebola-virus-infected or Lassa-virus-infected monkeys with mAbs once symptoms have appeared89,129. Unfortunately, no definitive evidence of the effectiveness of mAbs in Ebola-symptomatic or Lassa-symptomatic humans yet exists.

Camelid-derived single-domain antibodies (sdAbs), which contain a single heavy-chain variable domain, represent a promising new class of antibody-based therapeutics for RSV and other viruses that cause lower respiratory tract infections130,131,132,133. Because of their small size and high solubility and stability, sdAbs can be rapidly delivered to the site of infection via inhalation. Notably, a neutralizing anti-RSV sdAb (ALX-0171) that targets an epitope overlapping that bound by palivizumab recently showed a trend towards a therapeutic effect in a phase I and IIa clinical trial based on reduced viral loads and clinical symptoms in hospitalized RSV-infected infants. Prefusion F-protein-specific sdAbs that show up to 180,000 times greater neutralization potency than ALX-0171 have recently been identified and may offer even greater therapeutic benefit133.

Practical considerations

Intuitively, the enhanced potency of super-antibodies is immediately recognized as beneficial in antibody prophylaxis and therapy. However, there are also a number of additional effects from this enhanced potency that may not be instantly appreciated and that can be further strengthened by antibody engineering. For example, enhanced potency means that less antibody needs to be used, and this can enable easier-to-develop, low-concentration subcutaneous administration rather than the use of more-difficult-to-develop, high-concentration subcutaneously administered formulations or less-convenient (low-concentration) intravenous administration. Enhanced potency also means that the lifetime of an effective antibody following administration is extended, thereby requiring fewer administrations to maintain a useful protective or therapeutic effect. Antibody engineering can also extend its half-life considerably95,134,135,136,137,138,139 so that for the most potent super-antibodies, one could envisage requiring administrations perhaps only every 3–6 months for effectiveness. Antibody engineering can also deliver greater effectiveness through enhanced Fc effector function140,141.


The deployment of antibodies as antiviral agents has progressed through a number of stages over the years, corresponding to increasing levels of potency of the reagent administered. Passive immunotherapy began with immune serum over a century ago, then progressed to polyclonal antibodies, then mAbs and now into highly potent human mAbs dubbed super-antibodies. Thanks to research that has been primarily carried out in the field of cancer research, technologies have been developed to endow these super-antibodies with enhanced in vivo function.

Will super-antibodies change the landscape of antiviral prophylaxis and therapy? The answer to this question will depend on a number of factors: first, the rapidity of development of antiviral vaccines (vaccines will likely remain the least expensive and most effective antiviral measure, but some viruses such as HIV present a large challenge to vaccine development); second, the effective cost of antibody treatment, which incorporates not only manufacturing cost but also the durability of the administered antibody and the route of administration; and third, the success of antibodies in the treatment of established viral infections. Particularly in the therapeutic setting, the answers can only be obtained with clinical trials using the best super-antibodies available.

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Reviewer information

Nature Reviews Immunology thanks James Crowe Jr, Antonio Lanzavecchia and Gavin Screaton for their contribution to the peer review of this work.


  1. 1

    Hey, A. History and practice: antibodies in infectious diseases. Microbiol. Spectr. (2015).

  2. 2

    Graham, B. S. & Ambrosino, D. M. History of passive antibody administration for prevention and treatment of infectious diseases. Curr. Opin. HIV AIDS 10, 129–134 (2015). This article is an excellent account of the history of passive antibody administration.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  3. 3

    Sparrow, E., Friede, M., Sheikh, M. & Torvaldsen, S. Therapeutic antibodies for infectious diseases. Bull. World Health Organ. 95, 235–237 (2017).

    PubMed  PubMed Central  Article  Google Scholar 

  4. 4

    Berry, J. D. & Gaudet, R. G. Antibodies in infectious diseases: polyclonals, monoclonals and niche biotechnology. N. Biotechnol. 28, 489–501 (2011).

    Article  CAS  PubMed  Google Scholar 

  5. 5

    Saylor, C., Dadachova, E. & Casadevall, A. Monoclonal antibody-based therapies for microbial diseases. Vaccine 27 (Suppl. 6), G38–G46 (2009).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  6. 6

    Wilson, P. C. & Andrews, S. F. Tools to therapeutically harness the human antibody response. Nat. Rev. Immunol. 12, 709–719 (2012).

    Article  CAS  PubMed  Google Scholar 

  7. 7

    Burton, D. R. What are the most powerful immunogen design vaccine strategies? Reverse vaccinology 2.0 shows great promise. Cold Spring Harb. Perspect. Biol. 9, a030262 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  8. 8

    Chen, Z. et al. Cross-neutralizing human anti-poliovirus antibodies bind the recognition site for cellular receptor. Proc. Natl Acad. Sci. USA 110, 20242–20247 (2013).

    Article  CAS  PubMed  Google Scholar 

  9. 9

    Smith, S. A. et al. Isolation and characterization of broad and ultrapotent human monoclonal antibodies with therapeutic activity against Chikungunya virus. Cell Host Microbe 18, 86–95 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  10. 10

    Tahara, M. et al. Functional and structural characterization of neutralizing epitopes of measles virus hemagglutinin protein. J. Virol. 87, 666–675 (2013).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  11. 11

    Gilman, M. S. et al. Rapid profiling of RSV antibody repertoires from the memory B cells of naturally infected adult donors. Sci. Immunol. 1, eaaj1879 (2016).

    PubMed  PubMed Central  Article  Google Scholar 

  12. 12

    Corti, D. et al. Cross-neutralization of four paramyxoviruses by a human monoclonal antibody. Nature 501, 439–443 (2013). This paper is one of the first descriptions of an mAb with pan-virus-type neutralizing ability.

    Article  CAS  PubMed  Google Scholar 

  13. 13

    Macagno, A. et al. Isolation of human monoclonal antibodies that potently neutralize human cytomegalovirus infection by targeting different epitopes on the gH/gL/UL128-131A complex. J. Virol. 84, 1005–1013 (2010).

    Article  CAS  PubMed  Google Scholar 

  14. 14

    Stettler, K. et al. Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science 353, 823–826 (2016).

    Article  CAS  PubMed  Google Scholar 

  15. 15

    Sommerstein, R. et al. Arenavirus glycan shield promotes neutralizing antibody evasion and protracted infection. PLoS Pathog. 11, e1005276 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  16. 16

    Sather, D. N. et al. Factors associated with the development of cross-reactive neutralizing antibodies during human immunodeficiency virus type 1 infection. J. Virol. 83, 757–769 (2009).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. 17

    Gray, E. S. et al. The neutralization breadth of HIV-1 develops incrementally over four years and is associated with CD4+ T cell decline and high viral load during acute infection. J. Virol. 85, 4828–4840 (2011).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  18. 18

    Doria-Rose, N. A. et al. Breadth of human immunodeficiency virus-specific neutralizing activity in sera: clustering analysis and association with clinical variables. J. Virol. 84, 1631–1636 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  19. 19

    Simek, M. D. et al. Human immunodeficiency virus type 1 elite neutralizers: individuals with broad and potent neutralizing activity identified by using a high-throughput neutralization assay together with an analytical selection algorithm. J. Virol. 83, 7337–7348 (2009). This study describes the assembly and use of a large cohort of HIV-infected individuals with broad neutralizing sera as the starting point for super-antibody generation.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  20. 20

    Jahrling, P. B., Frame, J. D., Rhoderick, J. B. & Monson, M. H. Endemic Lassa fever in Liberia. IV. Selection of optimally effective plasma for treatment by passive immunization. Trans. R. Soc. Trop. Med. Hyg. 79, 380–384 (1985).

    Article  CAS  PubMed  Google Scholar 

  21. 21

    Andrews, S. F. et al. Immune history profoundly affects broadly protective B cell responses to influenza. Sci. Transl Med. 7, 316ra192 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  22. 22

    Kwong, P. D. & Mascola, J. R. Human antibodies that neutralize HIV-1: identification, structures, and B cell ontogenies. Immunity 37, 412–425 (2012).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  23. 23

    Burton, D. R. & Mascola, J. R. Antibody responses to envelope glycoproteins in HIV-1 infection. Nat. Immunol. 16, 571–576 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  24. 24

    Kwong, P. D., Mascola, J. R. & Nabel, G. J. Broadly neutralizing antibodies and the search for an HIV-1 vaccine: the end of the beginning. Nat. Rev. Immunol. 13, 693–701 (2013).

    Article  CAS  Google Scholar 

  25. 25

    Burton, D. R. & Hangartner, L. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu. Rev. Immunol. 34, 635–659 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  26. 26

    West, A. P. Jr et al. Structural insights on the role of antibodies in HIV-1 vaccine and therapy. Cell 156, 633–648 (2014).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  27. 27

    Corti, D. & Lanzavecchia, A. Broadly neutralizing antiviral antibodies. Annu. Rev. Immunol. 31, 705–742 (2013). This article is a comprehensive review of bnAbs against multiple viruses.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. 28

    Li, Y. et al. Immune history shapes specificity of pandemic H1N1 influenza antibody responses. J. Exp. Med. 210, 1493–1500 (2013).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  29. 29

    Li, G. M. et al. Pandemic H1N1 influenza vaccine induces a recall response in humans that favors broadly cross-reactive memory B cells. Proc. Natl Acad. Sci. USA 109, 9047–9052 (2012).

    Article  PubMed  Google Scholar 

  30. 30

    Joyce, M. G. et al. Vaccine-induced antibodies that neutralize group 1 and group 2 influenza A viruses. Cell 166, 609–623 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  31. 31

    Andrews, S. F. et al. Preferential induction of cross-group influenza A hemagglutinin stem-specific memory B cells after H7N9 immunization in humans. Sci. Immunol. 2, eaan2676 (2017).

    Article  PubMed  Google Scholar 

  32. 32

    Lee, J. E. et al. Structure of the Ebola virus glycoprotein bound to an antibody from a human survivor. Nature 454, 177–182 (2008).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  33. 33

    Burton, D. R., Poignard, P., Stanfield, R. L. & Wilson, I. A. Broadly neutralizing antibodies present new prospects to counter highly antigenically diverse viruses. Science 337, 183–186 (2012).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  34. 34

    Burton, D. R. A vaccine for HIV type 1: the antibody perspective. Proc. Natl Acad. Sci. USA 94, 10018–10023 (1997).

    Article  CAS  PubMed  Google Scholar 

  35. 35

    Li, Y. et al. Broad HIV-1 neutralization mediated by CD4-binding site antibodies. Nat. Med. 13, 1032–1034 (2007).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  36. 36

    Medina-Ramirez, M. et al. Broadly cross-neutralizing antibodies in HIV-1 patients with undetectable viremia. J. Virol. 85, 5804–5813 (2011).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  37. 37

    Walker, L. M. et al. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science 326, 285–289 (2009). This article presents the isolation of the first of a new generation of HIV bnAbs and one of the first super-antibodies.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  38. 38

    Falkowska, E. et al. PGV04, an HIV-1 gp120 CD4 binding site antibody, is broad and potent in neutralization but does not induce conformational changes characteristic of CD4. J. Virol. 86, 4394–4403 (2012).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  39. 39

    Walker, L. M. et al. Broad neutralization coverage of HIV by multiple highly potent antibodies. Nature 477, 466–470 (2011).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  40. 40

    Sok, D. et al. Recombinant HIV envelope trimer selects for quaternary-dependent antibodies targeting the trimer apex. Proc. Natl Acad. Sci. USA 111, 17624–17629 (2014).

    Article  CAS  PubMed  Google Scholar 

  41. 41

    Falkowska, E. et al. Broadly neutralizing HIV antibodies define a glycan-dependent epitope on the prefusion conformation of gp41 on cleaved envelope trimers. Immunity 40, 657–668 (2014).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  42. 42

    Corti, D. et al. A neutralizing antibody selected from plasma cells that binds to group 1 and group 2 influenza A hemagglutinins. Science 333, 850–856 (2011). This article describes a very broad influenza virus-specific super-antibody of the type that indicates that a universal flu vaccine may be possible.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  43. 43

    De Benedictis, P. et al. Development of broad-spectrum human monoclonal antibodies for rabies post-exposure prophylaxis. EMBO Mol. Med. 8, 407–421 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  44. 44

    Robbiani, D. F. et al. Recurrent potent human neutralizing antibodies to Zika virus in Brazil and Mexico. Cell 169, 597–609.e11 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  45. 45

    Mestas, J. & Hughes, C. C. Of mice and not men: differences between mouse and human immunology. J. Immunol. 172, 2731–2738 (2004).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  46. 46

    Bonsignori, M. et al. Analysis of a clonal lineage of HIV-1 envelope V2/V3 conformational epitope-specific broadly neutralizing antibodies and their inferred unmutated common ancestors. J. Virol. 85, 9998–10009 (2011).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  47. 47

    Huang, J. et al. Identification of a CD4-binding-site antibody to HIV that evolved near-pan neutralization breadth. Immunity 45, 1108–1121 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  48. 48

    Doria-Rose, N. A. et al. Developmental pathway for potent V1V2-directed HIV-neutralizing antibodies. Nature 509, 55–62 (2014).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  49. 49

    Kwakkenbos, M. J. et al. Generation of stable monoclonal antibody-producing B cell receptor-positive human memory B cells by genetic programming. Nat. Med. 16, 123–128 (2010).

    Article  CAS  PubMed  Google Scholar 

  50. 50

    Robinson, J. E. et al. Most neutralizing human monoclonal antibodies target novel epitopes requiring both Lassa virus glycoprotein subunits. Nat. Commun. 7, 11544 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  51. 51

    McLellan, J. S. et al. Structure of RSV fusion glycoprotein trimer bound to a prefusion-specific neutralizing antibody. Science 340, 1113–1117 (2013).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  52. 52

    Gilchuk, I. et al. Cross-neutralizing and protective human antibody specificities to poxvirus infections. Cell 167, 684–694.e9 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  53. 53

    Corti, D. et al. Prophylactic and postexposure efficacy of a potent human monoclonal antibody against MERS coronavirus. Proc. Natl Acad. Sci. USA 112, 10473–10478 (2015).

    Article  CAS  PubMed  Google Scholar 

  54. 54

    Flyak, A. I. et al. Cross-reactive and potent neutralizing antibody responses in human survivors of natural ebolavirus infection. Cell 164, 392–405 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  55. 55

    Corti, D. et al. Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science 351, 1339–1342 (2016).

    Article  CAS  PubMed  Google Scholar 

  56. 56

    Misasi, J. et al. Structural and molecular basis for Ebola virus neutralization by protective human antibodies. Science 351, 1343–1346 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  57. 57

    Babcook, J. S., Leslie, K. B., Olsen, O. A., Salmon, R. A. & Schrader, J. W. A novel strategy for generating monoclonal antibodies from single, isolated lymphocytes producing antibodies of defined specificities. Proc. Natl Acad. Sci. USA 93, 7843–7848 (1996). This article provides the first description of single B cell technology for the isolation of multiple mAbs.

    Article  CAS  PubMed  Google Scholar 

  58. 58

    Tiller, T. et al. Efficient generation of monoclonal antibodies from single human B cells by single cell RT-PCR and expression vector cloning. J. Immunol. Methods 329, 112–124 (2008). This article describes the application of single B cell technology to the isolation of human mAbs.

    Article  CAS  PubMed  Google Scholar 

  59. 59

    Wardemann, H. et al. Predominant autoantibody production by early human B cell precursors. Science 301, 1374–1377 (2003).

    Article  CAS  Google Scholar 

  60. 60

    Wu, X. et al. Rational design of envelope identifies broadly neutralizing human monoclonal antibodies to HIV-1. Science 329, 856–861 (2010). This article presents the isolation of the prototype broadly neutralizing super-antibody to the CD4 binding site, VRC01.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  61. 61

    Zhou, T. et al. Structural basis for broad and potent neutralization of HIV-1 by antibody VRC01. Science 329, 811–817 (2010).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  62. 62

    Scheid, J. F. et al. Sequence and structural convergence of broad and potent HIV antibodies that mimic CD4 binding. Science 333, 1633–1637 (2011).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  63. 63

    Wu, X. et al. Focused evolution of HIV-1 neutralizing antibodies revealed by structures and deep sequencing. Science 333, 1593–1602 (2011).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  64. 64

    Bornholdt, Z. A. et al. Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science 351, 1078–1083 (2016). This article describes the isolation of large numbers of mAbs from an Ebola virus survivor immediately following the outbreak and rapid identification of super-antibodies.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  65. 65

    Scherer, E. M. et al. Characteristics of memory B cells elicited by a highly efficacious HPV vaccine in subjects with no pre-existing immunity. PLoS Pathog. 10, e1004461 (2014).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  66. 66

    Wec, A. Z. et al. Antibodies from a human survivor define sites of vulnerability for broad protection against ebolaviruses. Cell 169, 878–890.e15 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  67. 67

    Sok, D. et al. Rapid elicitation of broadly neutralizing antibodies to HIV by immunization in cows. Nature 548, 108–111 (2017). This article describes the reliable generation of broadly neutralizing HIV antibodies by simple immunization in cows, suggesting that this animal has special value in super-antibody generation.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  68. 68

    Zhao, X. et al. Immunization-elicited broadly protective antibody reveals ebolavirus fusion loop as a site of vulnerability. Cell 169, 891–904.e15 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  69. 69

    Stevens, R. H., Macy, E., Morrow, C. & Saxon, A. Characterization of a circulating subpopulation of spontaneous antitetanus toxoid antibody producing B cells following in vivo booster immunization. J. Immunol. 122, 2498–2504 (1979).

    CAS  PubMed  Google Scholar 

  70. 70

    Wrammert, J. et al. Rapid cloning of high-affinity human monoclonal antibodies against influenza virus. Nature 453, 667–671 (2008). This article provides a description of a plasmablast approach to super-antibody generation.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  71. 71

    Priyamvada, L. et al. B Cell responses during secondary Dengue virus infection are dominated by highly cross-reactive, memory-derived plasmablasts. J. Virol. 90, 5574–5585 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  72. 72

    Dejnirattisai, W. et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 16, 170–177 (2015).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  73. 73

    Nair, N. et al. VP4- and VP7-specific antibodies mediate heterotypic immunity to rotavirus in humans. Sci. Transl Med. 9, eaam5434 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  74. 74

    Silveira, E. L. et al. Vaccine-induced plasmablast responses in rhesus macaques: phenotypic characterization and a source for generating antigen-specific monoclonal antibodies. J. Immunol. Methods 416, 69–83 (2015).

    Article  CAS  PubMed  Google Scholar 

  75. 75

    Wrammert, J. et al. Broadly cross-reactive antibodies dominate the human B cell response against 2009 pandemic H1N1 influenza virus infection. J. Exp. Med. 208, 181–193 (2011).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  76. 76

    Rogers, T. F. et al. Zika virus activates de novo and cross-reactive memory B cell responses in dengue-experienced donors. Sci. Immunol. 2, eaan6809 (2017).

    PubMed  PubMed Central  Article  Google Scholar 

  77. 77

    Pascal, K. E. et al. Pre- and postexposure efficacy of fully human antibodies against Spike protein in a novel humanized mouse model of MERS-CoV infection. Proc. Natl Acad. Sci. USA 112, 8738–8743 (2015).

    Article  CAS  PubMed  Google Scholar 

  78. 78

    Luke, T. et al. Human polyclonal immunoglobulin G from transchromosomic bovines inhibits MERS-CoV in vivo. Sci. Transl Med. 8, 326ra21 (2016).

    Article  CAS  PubMed  Google Scholar 

  79. 79

    Hooper, J. W. et al. DNA vaccine-derived human IgG produced in transchromosomal bovines protect in lethal models of hantavirus pulmonary syndrome. Sci. Transl Med. 6, 264ra162 (2014).

    Article  CAS  PubMed  Google Scholar 

  80. 80

    Gardner, C. L. et al. Antibody preparations from human transchromosomic cows exhibit prophylactic and therapeutic efficacy against Venezuelan equine encephalitis virus. J. Virol. 91, e00226-17 (2017).

    PubMed  PubMed Central  Article  Google Scholar 

  81. 81

    Dye, J. M. et al. Production of potent fully human polyclonal antibodies against Ebola Zaire virus in transchromosomal cattle. Sci. Rep. 6, 24897 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  82. 82

    Sapparapu, G. et al. Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature 540, 443–447 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  83. 83

    Wang, Q. et al. Molecular determinants of human neutralizing antibodies isolated from a patient infected with Zika virus. Sci. Transl Med. 8, 369ra179 (2016).

    Article  CAS  PubMed  Google Scholar 

  84. 84

    Priyamvada, L. et al. Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc. Natl Acad. Sci. USA 113, 7852–7857 (2016).

    Article  CAS  PubMed  Google Scholar 

  85. 85

    Barba-Spaeth, G. et al. Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature 536, 48–53 (2016).

    Article  CAS  PubMed  Google Scholar 

  86. 86

    Beltramello, M. et al. The human immune response to Dengue virus is dominated by highly cross-reactive antibodies endowed with neutralizing and enhancing activity. Cell Host Microbe 8, 271–283 (2010).

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  87. 87

    Shingai, M. et al. Antibody-mediated immunotherapy of macaques chronically infected with SHIV suppresses viraemia. Nature 503, 277–280 (2013).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  88. 88

    Prabakaran, M. et al. Combination therapy using chimeric monoclonal antibodies protects mice from lethal H5N1 infection and prevents formation of escape mutants. PLoS ONE 4, e5672 (2009).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  89. 89

    Mire, C. E. et al. Human-monoclonal-antibody therapy protects nonhuman primates against advanced Lassa fever. Nat. Med. 23, 1146–1149 (2017). This study is the first demonstration in nonhuman primates that mAbs can protect against advanced Lassa fever.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  90. 90

    Magnani, D. M. et al. Neutralizing human monoclonal antibodies prevent Zika virus infection in macaques. Sci. Transl Med. 9, eaan8184 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  91. 91

    Xu, L. et al. Trispecific broadly neutralizing HIV antibodies mediate potent SHIV protection in macaques. Science 358, 85–90 (2017). This study provides a novel design of antibodies to cope with HIV diversity by incorporating three specificities into a single antibody-like molecule.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  92. 92

    Julg, B. et al. Protection against a mixed SHIV challenge by a broadly neutralizing antibody cocktail. Sci. Transl Med. 9, eaao4235 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  93. 93

    Wang, J. et al. A human bi-specific antibody against Zika virus with high therapeutic potential. Cell 171, 229–241.e15 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  94. 94

    [No authors listed.] Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 102, 531–537 (1998).

  95. 95

    Zhu, Q. et al. A highly potent extended half-life antibody as a potential RSV vaccine surrogate for all infants. Sci. Transl Med. 9, eaaj1928 (2017). This article is a description of an RSV-specific super-antibody that shows about ten times greater in vivo efficacy than palivizumab in cotton rats.

    Article  PubMed  Google Scholar 

  96. 96

    Sui, J. et al. Structural and functional bases for broad-spectrum neutralization of avian and human influenza A viruses. Nat. Struct. Mol. Biol. 16, 265–273 (2009).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  97. 97

    Qiu, X. et al. Ebola GP-specific monoclonal antibodies protect mice and guinea pigs from lethal Ebola virus infection. PLoS Negl. Trop. Dis. 6, e1575 (2012).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  98. 98

    Wilson, J. A. et al. Epitopes involved in antibody-mediated protection from Ebola virus. Science 287, 1664–1666 (2000).

    Article  CAS  PubMed  Google Scholar 

  99. 99

    Mascola, J. R. et al. Protection of Macaques against pathogenic simian/human immunodeficiency virus 89.6PD by passive transfer of neutralizing antibodies. J. Virol. 73, 4009–4018 (1999).

    PubMed  PubMed Central  CAS  Google Scholar 

  100. 100

    Mascola, J. R. et al. Protection of macaques against vaginal transmission of a pathogenic HIV-1/SIV chimeric virus by passive infusion of neutralizing antibodies. Nat. Med. 6, 207–210 (2000).

    Article  CAS  PubMed  Google Scholar 

  101. 101

    Parren, P. W. et al. Antibody protects macaques against vaginal challenge with a pathogenic R5 simian/human immunodeficiency virus at serum levels giving complete neutralization in vitro. J. Virol. 75, 8340–8347 (2001).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  102. 102

    Paules, C. I. et al. The hemagglutinin A stem antibody MEDI8852 prevents and controls disease and limits transmission of pandemic influenza viruses. J. Infect. Dis. 216, 356–365 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  103. 103

    Hessell, A. J. et al. Effective, low-titer antibody protection against low-dose repeated mucosal SHIV challenge in macaques. Nat. Med. 15, 951–954 (2009).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  104. 104

    Hessell, A. J. et al. Broadly neutralizing human anti-HIV antibody 2G12 is effective in protection against mucosal SHIV challenge even at low serum neutralizing titers. PLoS Pathog. 5, e1000433 (2009).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  105. 105

    Shingai, M. et al. Passive transfer of modest titers of potent and broadly neutralizing anti-HIV monoclonal antibodies block SHIV infection in macaques. J. Exp. Med. 211, 2061–2074 (2014).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  106. 106

    Julg, B. et al. Broadly neutralizing antibodies targeting the HIV-1 envelope V2 apex confer protection against a clade C SHIV challenge. Sci. Transl Med. 9, eaal1321 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  107. 107

    Deal, C. E. & Balazs, A. B. Vectored antibody gene delivery for the prevention or treatment of HIV infection. Curr. Opin. HIV AIDS 10, 190–197 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  108. 108

    Johnson, P. R. et al. Vector-mediated gene transfer engenders long-lived neutralizing activity and protection against SIV infection in monkeys. Nat. Med. 15, 901–906 (2009). This article is the initial report of vectored prophylaxis applied in macaques.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  109. 109

    Gardner, M. R. et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519, 87–91 (2015). The article describes the extreme breadth for an engineered antibody molecule incorporating novel features.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  110. 110

    Balazs, A. B. et al. Antibody-based protection against HIV infection by vectored immunoprophylaxis. Nature 481, 81–84 (2011). This is a study developing vectored immunoprophylaxis for HIV.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  111. 111

    Saunders, K. O. et al. Sustained delivery of a broadly neutralizing antibody in nonhuman primates confers long-term protection against simian/human immunodeficiency virus infection. J. Virol. 89, 5895–5903 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  112. 112

    Flingai, S. et al. Protection against dengue disease by synthetic nucleic acid antibody prophylaxis/immunotherapy. Sci. Rep. 5, 12616 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  113. 113

    Muthumani, K. et al. Optimized and enhanced DNA plasmid vector based in vivo construction of a neutralizing anti-HIV-1 envelope glycoprotein Fab. Hum. Vaccines Immunother. 9, 2253–2262 (2013).

    Article  CAS  Google Scholar 

  114. 114

    Pardi, N. et al. Administration of nucleoside-modified mRNA encoding broadly neutralizing antibody protects humanized mice from HIV-1 challenge. Nat. Commun. 8, 14630 (2017).

    PubMed  PubMed Central  Article  Google Scholar 

  115. 115

    Nault, J. C. et al. Recurrent AAV2-related insertional mutagenesis in human hepatocellular carcinomas. Nat. Genet. 47, 1187–1193 (2015).

    Article  CAS  PubMed  Google Scholar 

  116. 116

    Gao, G. et al. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 103, 3300–3302 (2004).

    Article  CAS  PubMed  Google Scholar 

  117. 117

    Tjelle, T. E. et al. Monoclonal antibodies produced by muscle after plasmid injection and electroporation. Mol. Ther. 9, 328–336 (2004).

    Article  CAS  PubMed  Google Scholar 

  118. 118

    Hu, J. & Robinson, J. L. Treatment of respiratory syncytial virus with palivizumab: a systematic review. World J. Pediatr. 6, 296–300 (2010).

    Article  CAS  PubMed  Google Scholar 

  119. 119

    Barouch, D. H. et al. Therapeutic efficacy of potent neutralizing HIV-1-specific monoclonal antibodies in SHIV-infected rhesus monkeys. Nature 503, 224–228 (2013). This study describes a surprisingly effective monotherapy for SHIV infection in macaques.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  120. 120

    Horwitz, J. A. et al. HIV-1 suppression and durable control by combining single broadly neutralizing antibodies and antiretroviral drugs in humanized mice. Proc. Natl Acad. Sci. USA 110, 16538–16543 (2013).

    Article  PubMed  Google Scholar 

  121. 121

    Poignard, P. et al. Neutralizing antibodies have limited effects on the control of established HIV-1 infection in vivo. Immunity 10, 431–438 (1999).

    Article  CAS  PubMed  Google Scholar 

  122. 122

    Caskey, M. et al. Viraemia suppressed in HIV-1-infected humans by broadly neutralizing antibody 3BNC117. Nature 522, 487–491 (2015). This article describes the first use of a super-antibody in HIV infection in humans.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  123. 123

    Scheid, J. F. et al. HIV-1 antibody 3BNC117 suppresses viral rebound in humans during treatment interruption. Nature 535, 556–560 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  124. 124

    Caskey, M. et al. Antibody 10–1074 suppresses viremia in HIV-1-infected individuals. Nat. Med. 23, 185–191 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  125. 125

    Lynch, R. M. et al. Virologic effects of broadly neutralizing antibody VRC01 administration during chronic HIV-1 infection. Sci. Transl Med. 7, 319ra206 (2015).

    Article  CAS  PubMed  Google Scholar 

  126. 126

    Bar, K. J. et al. Effect of HIV antibody VRC01 on viral rebound after treatment interruption. N. Engl. J. Med. 375, 2037–2050 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  127. 127

    Schoofs, T. et al. HIV-1 therapy with monoclonal antibody 3BNC117 elicits host immune responses against HIV-1. Science 352, 997–1001 (2016). This article describes how super-antibody HIV therapy appears to enhance host immune responses in general.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  128. 128

    Zeitlin, L. et al. Monoclonal antibody therapy for Junin virus infection. Proc. Natl Acad. Sci. USA 113, 4458–4463 (2016).

    Article  CAS  PubMed  Google Scholar 

  129. 129

    Qiu, X. et al. Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature 514, 47–53 (2014). This study is the first demonstration of successful antibody therapy against established Ebola virus disease in nonhuman primates.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  130. 130

    Van Heeke, G. et al. Nanobodies® as inhaled biotherapeutics for lung diseases. Pharmacol. Ther. 169, 47–56 (2017).

    Article  CAS  PubMed  Google Scholar 

  131. 131

    Schepens, B. et al. Nanobodies® specific for respiratory syncytial virus fusion protein protect against infection by inhibition of fusion. J. Infect. Dis. 204, 1692–1701 (2011).

    Article  CAS  PubMed  Google Scholar 

  132. 132

    Detalle, L. et al. Generation and characterization of ALX-0171, a potent novel therapeutic nanobody for the treatment of respiratory syncytial virus infection. Antimicrob. Agents Chemother. 60, 6–13 (2015).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  133. 133

    Rossey, I. et al. Potent single-domain antibodies that arrest respiratory syncytial virus fusion protein in its prefusion state. Nat. Commun. 8, 14158 (2017). This article describes the use of a single-domain antibody against RSV.

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  134. 134

    Hinton, P. R. et al. Engineered human IgG antibodies with longer serum half-lives in primates. J. Biol. Chem. 279, 6213–6216 (2004).

    Article  CAS  PubMed  Google Scholar 

  135. 135

    Dall'Acqua, W. F., Kiener, P. A. & Wu, H. Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn). J. Biol. Chem. 281, 23514–23524 (2006).

    Article  CAS  PubMed  Google Scholar 

  136. 136

    Zalevsky, J. et al. Enhanced antibody half-life improves in vivo activity. Nat. Biotechnol. 28, 157–159 (2010).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  137. 137

    Yu, X. Q. et al. Safety, tolerability, and pharmacokinetics of MEDI4893, an investigational, extended-half-life, anti-Staphylococcus aureus alpha-toxin human monoclonal antibody, in healthy adults. Antimicrob. Agents Chemother. 61, e01020-16 (2017).

    Article  PubMed  Google Scholar 

  138. 138

    Ko, S. Y. et al. Enhanced neonatal Fc receptor function improves protection against primate SHIV infection. Nature 514, 642–645 (2014).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  139. 139

    Gautam, R. et al. A single injection of anti-HIV-1 antibodies protects against repeated SHIV challenges. Nature 533, 105–109 (2016).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  140. 140

    Lazar, G. A. et al. Engineered antibody Fc variants with enhanced effector function. Proc. Natl Acad. Sci. USA 103, 4005–4010 (2006).

    Article  CAS  PubMed  Google Scholar 

  141. 141

    Presta, L. G. Molecular engineering and design of therapeutic antibodies. Curr. Opin. Immunol. 20, 460–470 (2008). This is a review of strategies for enhancing antibody effector function.

    Article  CAS  PubMed  Google Scholar 

  142. 142

    Bowers, P. M. et al. Coupling mammalian cell surface display with somatic hypermutation for the discovery and maturation of human antibodies. Proc. Natl Acad. Sci. USA 108, 20455–20460 (2011).

    Article  PubMed  Google Scholar 

  143. 143

    Boder, E. T. & Wittrup, K. D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15, 553–557 (1997).

    Article  CAS  PubMed  Google Scholar 

  144. 144

    McCafferty, J., Griffiths, A. D., Winter, G. & Chiswell, D. J. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 348, 552–554 (1990).

    Article  CAS  PubMed  Google Scholar 

  145. 145

    Huse, W. D. et al. Generation of a large combinatorial library of the immunoglobulin repertoire in phage lambda. Science 246, 1275–1281 (1989).

    Article  CAS  PubMed  Google Scholar 

  146. 146

    Lee, E. C. et al. Complete humanization of the mouse immunoglobulin loci enables efficient therapeutic antibody discovery. Nat. Biotechnol. 32, 356–363 (2014).

    Article  CAS  PubMed  Google Scholar 

  147. 147

    Murphy, A. J. et al. Mice with megabase humanization of their immunoglobulin genes generate antibodies as efficiently as normal mice. Proc. Natl Acad. Sci. USA 111, 5153–5158 (2014).

    Article  CAS  PubMed  Google Scholar 

  148. 148

    Scheid, J. F. et al. A method for identification of HIV gp140 binding memory B cells in human blood. J. Immunol. Methods 343, 65–67 (2009).

    Article  CAS  PubMed  Google Scholar 

  149. 149

    Lanzavecchia, A., Corti, D. & Sallusto, F. Human monoclonal antibodies by immortalization of memory B cells. Curr. Opin. Biotechnol. 18, 523–528 (2007).

    Article  CAS  PubMed  Google Scholar 

  150. 150

    Huang, J. et al. Isolation of human monoclonal antibodies from peripheral blood B cells. Nat. Protoc. 8, 1907–1915 (2013).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  151. 151

    Lee, J. H. et al. A broadly neutralizing antibody targets the dynamic HIV envelope trimer apex via a long, rigidified, and anionic beta-hairpin structure. Immunity 46, 690–702 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  152. 152

    McCoy, L. E. & Burton, D. R. Identification and specificity of broadly neutralizing antibodies against HIV. Immunol. Rev. 275, 11–20 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  153. 153

    Dreyfus, C. et al. Highly conserved protective epitopes on influenza B viruses. Science 337, 1343–1348 (2012).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  154. 154

    Corti, D. et al. Tackling influenza with broadly neutralizing antibodies. Curr. Opin. Virol. 24, 60–69 (2017).

    Article  CAS  PubMed  Google Scholar 

  155. 155

    Wu, N. C. & Wilson, I. A. A. Perspective on the structural and functional constraints for immune evasion: insights from influenza virus. J. Mol. Biol. 429, 2694–2709 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

  156. 156

    Wen, X. et al. Structural basis for antibody cross-neutralization of respiratory syncytial virus and human metapneumovirus. Nat. Microbiol. 2, 16272 (2017).

    PubMed  PubMed Central  Article  CAS  Google Scholar 

Download references


The authors thank J. Mascola, D. Sok and M. Vasquez for comments on the manuscript. The authors also thank L. Hangartner and C. Corbaci for assistance with figure preparation. D.R.B. acknowledges the financial support from the US National Institute of Allergy and Infectious Disease, the International AIDS Vaccine Initiative, the Bill and Melinda Gates Foundation and the Ragon Institute.

Author information




Both authors contributed to research and discussion of the content of the article and to writing, reviewing and editing of the manuscript before submission.

Corresponding authors

Correspondence to Laura M. Walker or Dennis R. Burton.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links


The AMP study

PowerPoint slides


Humanized mouse antibodies

Genetically engineered mouse antibodies in which the protein sequence has been modified to increase its similarity to human antibodies, thereby decreasing its potential immunogenicity.

Transchromosomal cows

Cows that have been genetically modified to incorporate human chromosomes so that upon immunization they generate human antibodies.

Antibody-dependent cellular cytotoxicity

(ADCC). A mechanism by which Fc receptor-bearing effector cells such as natural killer (NK) cells recognize and kill antibody-coated target cells, such as virus-infected cells. The Fc portions of the coating antibodies interact with an Fc receptor (for example, FcγRIII; which is expressed by NK cells), thereby initiating a signalling cascade that results in the release of cytotoxic granules (containing perforin and granzyme B) from the effector cell, which lead to cell death of the antibody-coated cell.

Complement-dependent cytotoxicity

A mechanism of antibody-mediated immunity whereby the association of an antibody on a target cell surface leads to binding of the complement component C1q and triggering of the classical complement cascade. The cascade leads to elimination of target cells by a number of mechanisms, including the formation of the membrane attack complex, the cytolytic end product of the complement cascade.

Hyperimmune globulins

Antibody preparations generated from plasma of donors with high titres of an antibody against a specific pathogen or antigen. Hyperimmune globulins are available against rabies virus, hepatitis B virus and varicella zoster virus, among other viruses.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Walker, L., Burton, D. Passive immunotherapy of viral infections: 'super-antibodies' enter the fray. Nat Rev Immunol 18, 297–308 (2018).

Download citation

Further reading


Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing